VIRAL MALIGNANCY
病毒性恶性肿瘤
基本信息
- 批准号:6653298
- 负责人:
- 金额:$ 18.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-08-29 至 2003-04-30
- 项目状态:已结题
- 来源:
- 关键词:AIDS related neoplasm /cancer Epstein Barr virus clinical research cytomegalovirus deltaretrovirus hepatitis B virus group host organism interaction human herpesvirus 8 human immunodeficiency virus human subject infectious hepatitis microarray technology viral carcinogenesis virus related neoplasm /cancer virus virus interaction
项目摘要
The Viral Malignancy Program consists of 12 Participating and Distinguished Members, representing total peer-reviewed funding of nearly $5.5 Million in annual direct costs ($6.9 Million in total costs). During the last two years, its Members were responsible for a total of 55 cancer relevant, peer-reviewed publications 56% of which were intra-and inter-programmatic collaborations. Research on viral malignancies presents a unique opportunity for our understanding of oncogenesis and means for targeted intervention. The Viral Malignancy Program at the UCSD Cancer Center consists of a longstanding cohesive group of researchers, with wide-ranging expertise in oncogenic viruses. The current primary interests of the Program Members are focused on human retroviruses (including both HIV and HTLV), EBV, HHV-8 and HBV/HCV. Program Members investigate the pathogenesis of malignancies induced by these viruses as well as develop and test reagents such as ribozyme gene therapy, to combat these oncogenic viruses and/or their associated malignancies. Work on host- virus interactions has spawned numerous interactions and collaborations to developed and implement high-density array technology for analysis of cellular gene expression. In the induction and progression of viral malignancy. Members also study interactions between hepatitis and AIDS viruses in inducing neoplasia. Clinical trials are in progress to test a number of new anti-viral strategies in AIDS-related or hepatitis-related malignancies.
病毒恶性肿瘤计划由12名参与和杰出成员组成,代表了近550万美元的年度直接成本(690万美元的总成本)的总同行评审资金。在过去的两年中,其成员总共负责55个相关的癌症,同行评审的出版物,其中56%是内部和程序间合作。 关于病毒恶性肿瘤的研究为我们理解肿瘤发生和有针对性干预的手段提供了一个独特的机会。 UCSD癌症中心的病毒恶性肿瘤计划由一群长期的研究人员组成,具有广泛的致癌病毒专业知识。该计划成员的当前主要利益集中在人类逆转录病毒(包括HIV和HTLV),EBV,HHV-8和HBV/HCV上。计划成员研究这些病毒引起的恶性肿瘤的发病机理,以及开发和测试核酶基因治疗等试剂,以对抗这些致癌病毒和/或其相关的恶性肿瘤。关于宿主病毒相互作用的工作催生了许多相互作用和协作,以开发和实施高密度阵列技术,以分析细胞基因表达。在病毒恶性肿瘤的诱导和进展中。成员还研究肝炎与艾滋病病毒在诱导肿瘤中的相互作用。正在进行临床试验,以测试与艾滋病相关或与肝炎有关的恶性肿瘤中的许多新的抗病毒策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
William Wachsman其他文献
William Wachsman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('William Wachsman', 18)}}的其他基金
AIDS-RELATED MALIGNANCIES CONSORTIUM--UC SAN DIEGO
艾滋病相关恶性肿瘤协会--加州大学圣地亚哥分校
- 批准号:
7110621 - 财政年份:1999
- 资助金额:
$ 18.37万 - 项目类别:
相似海外基金
Project 2: Novel investigation of Epstein-Barr virus as a potential cause of conjunctival squamous cell carcinoma among people living with HIV in Zimbabwe
项目 2:对 Epstein-Barr 病毒作为津巴布韦艾滋病毒感染者结膜鳞状细胞癌潜在原因的新调查
- 批准号:
10598376 - 财政年份:2023
- 资助金额:
$ 18.37万 - 项目类别:
The Ubiquitin Sensor p62 Is A Novel Component of EBV LMP1 Signalosome
泛素传感器 p62 是 EBV LMP1 信号体的新型成分
- 批准号:
10202127 - 财政年份:2021
- 资助金额:
$ 18.37万 - 项目类别:
Phase one clinical trial of a novel small molecule EBNA1 inhibitor, VK-2019, in patients with Epstein- Barr positive nasopharyngeal cancer, with pharmacokinetic and pharmacodynamic correlative studies
新型小分子 EBNA1 抑制剂 VK-2019 在 Epstein-Barr 阳性鼻咽癌患者中的一期临床试验,并进行药代动力学和药效学相关研究
- 批准号:
10608154 - 财政年份:2019
- 资助金额:
$ 18.37万 - 项目类别:
LIMD1 Is a Novel Marker Associated with IRF4 in EBV Latency and Lymphoma
LIMD1 是 EBV 潜伏期和淋巴瘤中与 IRF4 相关的新型标记物
- 批准号:
9409873 - 财政年份:2017
- 资助金额:
$ 18.37万 - 项目类别:
Noncoding RNAs in gamma-Herpesvirus Biology and AIDS Malignancies
γ-疱疹病毒生物学和艾滋病恶性肿瘤中的非编码 RNA
- 批准号:
10646224 - 财政年份:2017
- 资助金额:
$ 18.37万 - 项目类别: